A. Lo

Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.

S. Anderson, R. Forshee, T. MaCurdy, 2021, JAMA internal medicine.

Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.

S. Anderson, E. Woo, R. Forshee, 2020, The Journal of infectious diseases.

A simulation study of the statistical power and signaling characteristics of an early season sequential test for influenza vaccine safety

S. Anderson, R. Forshee, T. MaCurdy, 2019, Pharmacoepidemiology and drug safety.

Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season.

R. Forshee, T. MaCurdy, J. Kelman, 2019, Vaccine.

Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years

R. Forshee, T. MaCurdy, A. Shoaibi, 2022, Vaccine.

Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy

T. MaCurdy, D. Graham, J. Kelman, 2022, Drugs & Therapy Perspectives.

Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle

T. MaCurdy, D. Graham, J. Kelman, 2021, Pharmacoepidemiology and drug safety.